Study on Infectious Mononucleosis in Munich

Status Completed

Clinical Trial Summary

This observational clinical study aims at the identification of novel biomarkers and causative factors of complicated and/or protracted Epstein-Barr virus-associated infectious mononucleosis (IM). Clinical, biochemical, and routine virological data were collected from 200 patients with IM, novel analytical tools were implemented, and immunological and virological experimental data were generated using blood samples and mouthwashes. Patients have been investigated within four weeks after the onset of symptoms as well as one month and six months thereafter.

Clinical Trial Description

EBV-associated diseases are a severe and global health problem, and novel tools and targets for a better pathogenetic understanding, diagnosis, treatment, and prevention are clearly needed. Here we propose to use several novel experimental approaches to investigate immunological, virological, biochemical, and clinical features in an observational study on Munich IM patients. This study aims at identifying biomarkers and causative factors of protracted and/or complicated IM to facilitate the development of novel approaches to early diagnosis, therapy, and prevention of severe, life-threatening, and chronic EBV-associated diseases, including post-viral syndromes. Two hundred patients with IM onset within the last four weeks were recruited from Munich health care institutions and were re-investigated at one and six months after the onset of symptoms. A novel diagnostic scoring system was developed to indicate the severity, complexity, and protraction of symptoms. Investigated clinical parameters, including reported symptoms and physical signs of IM, as well as candidate risk factors in the medical history of patients and family members. Peripheral blood was analysed by established and novel analytical assays to determine the immunological and virological phenotypes of IM, and viral load was determined in mouthwashes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06002802
Study type	Observational
Source	Technical University of Munich
Contact
Status	Completed
Phase
Start date	March 1, 2016
Completion date	August 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01256853` - Modified Vaccinia Ankara (MVA) Vaccine Study	Phase 1
Completed	`NCT00070785` - Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations	N/A
Recruiting	`NCT01248598` - The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis	N/A
Completed	`NCT00701922` - Surveillance Study of Viral Infections Following Lung Transplantation	N/A
Recruiting	`NCT02580539` - A Study of the Safety and Efficacy of EBV Specific T-cell Lines	Phase 1/Phase 2
Completed	`NCT03546101` - Early Detection of Epstein-Barr Virus Related Disease.
Recruiting	`NCT05183490` - R-MVST Cells for Treatment of Viral Infections	Phase 1
Completed	`NCT00058812` - Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts	Phase 1
Completed	`NCT01094405` - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy	Phase 2
Terminated	`NCT05305040` - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Completed	`NCT02335437` - Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents	N/A
Recruiting	`NCT03266653` - EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection	Phase 2
Recruiting	`NCT04507477` - Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial	Phase 1/Phase 2
Completed	`NCT00963248` - EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients	N/A
Recruiting	`NCT06027879` - Anti-viral T-cell Therapy by Gamma Capture	Phase 1/Phase 2
Recruiting	`NCT05592626` - A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT02715752` - A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin	N/A
Completed	`NCT01070797` - Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)	Phase 1
Completed	`NCT00058604` - Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).	Phase 1
Completed	`NCT00058591` - Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study on Infectious Mononucleosis in Munich — IMMUC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms